PMID- 35461744
OWN - NLM
STAT- MEDLINE
DCOM- 20220802
LR  - 20220906
IS  - 1879-0828 (Electronic)
IS  - 0953-6205 (Linking)
VI  - 102
DP  - 2022 Aug
TI  - Efficacy and safety of Janus kinase inhibitors in patients with ankylosing 
      spondylitis: A systematic review and meta-analysis.
PG  - 47-53
LID - S0953-6205(22)00143-1 [pii]
LID - 10.1016/j.ejim.2022.04.007 [doi]
AB  - OBJECTIVES: To assess the efficacy and safety of janus kinase (JAK) inhibitors in 
      the treatment of ankylosing spondylitis (AS). METHODS: We searched the PubMed and 
      Cochrane Central Register of Controlled Trials to Nov 1, 2021. We included all 
      randomized controlled trials (RCTs) evaluating JAK inhibitors in the treatment of 
      AS. Two reviewers independently selected studies, extracted data and assessed the 
      risk of bias. RESULTS: Four RCT studies with 779 participants were included in 
      the meta-analysis. Compared with placebo group, percentages of participants 
      achieving responses of Assessment of spondyloarthritis international 
      society(ASAS) 20, ASAS 40, ASAS 5/6, Bath AS disease activity index (BASDAI) 50 
      were significantly higher in JAK inhibitor group respectively; changes from 
      baseline in AS disease activity score using C-reactive protein(ASDAS-CRP), 
      Maastricht AS enthesitis score (MASES), AS Quality of Life (ASQoL) score, 
      short-form-36 health survey physical component summary (SF-36 PCS) score, BASDAI, 
      Bath AS functional index (BASFI), Bath AS metrology index (BASMI), Functional 
      Assessment of Chronic Illness Therapy-fatigue (FACIT-F) score, SPARCC joint score 
      and Work Productivity and Activity Impairment (WPAI) Overall Work Impairment 
      score showed significant improvements in JAK inhibitor group. The incidence of 
      adverse events (AEs) and severe adverse events (SAEs) showed no significant 
      differences between the JAK inhibitor and placebo groups. CONCLUSIONS: JAK 
      inhibitors showed a satisfactory and promising efficacy in the treatment of 
      active AS not only in mitigating disease activity, but also substantially 
      improving patient's physical function, emotional well-being and social 
      participation. The results of this meta-analysis provide solid evidence for JAK 
      inhibitor as a novel therapeutic strategy for patients with active AS.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Li, Shu
AU  - Li S
AD  - Department of Rheumatology, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Li, Fen
AU  - Li F
AD  - Department of Rheumatology, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Mao, Ni
AU  - Mao N
AD  - Department of Rheumatology, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Wang, Jia
AU  - Wang J
AD  - Department of Rheumatology, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Xie, Xi
AU  - Xie X
AD  - Department of Rheumatology, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China. Electronic address: hsixie1997@csu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220420
PL  - Netherlands
TA  - Eur J Intern Med
JT  - European journal of internal medicine
JID - 9003220
RN  - 0 (Janus Kinase Inhibitors)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
CIN - Eur J Intern Med. 2022 Sep;103:107-108. PMID: 35667942
CIN - Eur J Intern Med. 2022 Sep;103:109-110. PMID: 35840508
MH  - C-Reactive Protein/analysis
MH  - Fatigue
MH  - Humans
MH  - *Janus Kinase Inhibitors/therapeutic use
MH  - Quality of Life
MH  - Severity of Illness Index
MH  - *Spondylitis, Ankylosing/drug therapy
OTO - NOTNLM
OT  - Ankylosing spondylitis
OT  - Janus kinase inhibitor
OT  - Meta-analysis
OT  - Systematic review
EDAT- 2022/04/25 06:00
MHDA- 2022/08/03 06:00
CRDT- 2022/04/24 20:21
PHST- 2021/12/21 00:00 [received]
PHST- 2022/04/05 00:00 [revised]
PHST- 2022/04/07 00:00 [accepted]
PHST- 2022/04/25 06:00 [pubmed]
PHST- 2022/08/03 06:00 [medline]
PHST- 2022/04/24 20:21 [entrez]
AID - S0953-6205(22)00143-1 [pii]
AID - 10.1016/j.ejim.2022.04.007 [doi]
PST - ppublish
SO  - Eur J Intern Med. 2022 Aug;102:47-53. doi: 10.1016/j.ejim.2022.04.007. Epub 2022 
      Apr 20.